Investigational Drug Details
| Drug ID: | D438 |
| Drug Name: | Levoketoconazole |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB05667 |
| DrugBank Description: | Levoketoconazole is a cortisol synthesis inhibitor that is being developed as a therapy for glucose and cholesterol control in patients with type 2 diabetes mellitus. |
| PubChem ID: | 47576 |
| CasNo: | 142128-57-2 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1 |
| Structure: |
|
| InChiKey: | XMAYWYJOQHXEEK-ZEQKJWHPSA-N |
| Molecular Weight: | 531.431 |
| DrugBank Targets: | Steroid 17-alpha-hydroxylase/17,20 lyase; Cytochrome P450 11B1, mitochondrial; Cytochrome P450 11B2, mitochondrial; Cholesterol side-chain cleavage enzyme, mitochondrial; Lanosterol 14-alpha demethylase |
| DrugBank MoA: | Preliminary data suggests that DIO-902 increases insulin sensitivity by lowering cortisol levels. The primary mechanism of action is via inhibition of the 11-β-hydroxylase enzyme, the terminal step in cortisol synthesis in the adrenal gland. DIO-902 has also been shown to lower total and LDL-cholesterol by inhibiting 14-α-demethylase, a key enzyme in cholesterol synthesis. In combination with a typical glucose-lowering agent, such as metformin, DIO-902 may enhance glucose control and improve total and LDL-cholesterol. [DiObex Press Release] |
| DrugBank Pharmacology: | |
| DrugBank Indication: | Investigated for use/treatment in diabetes mellitus type 2. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|